In a hotel room in Santa Clara, Calif., five members of the AI company Anthropic huddled around a laptop, working urgently. It was February 2025, and they had been at a conference nearby when they ...
It's not looking too good for the biotech.
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
The incident on Saturday has further fuelled tensions between France's far right and hard left ahead of municipal elections nationwide in March and the 2027 presidential race. French government ...
Recursion Pharmaceuticals beat estimated earnings by 30.0%, reporting an EPS of $-0.21 versus an estimate of $-0.3. Revenue was up $30.99 million from the same period last year. During the previous ...
Paris, France — France's hard-left France Unbowed party said Wednesday it had to evacuate its Paris headquarters following a "bomb threat," after it was accused of having some responsibility for the ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
THE FATAL beating of a 23-year-old nationalist in Lyon on February 12th is France’s “Charlie Kirk moment”, said Dominique de Villepin. France’s far right, the former prime minister warned, would use ...
Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
All the Latest Game Footage and Images from Soul Recursion Soul Recursion is a story focused hack and slash challenging you to explore and uncover the mysteries hidden amongst utopian ruins. Games ...
Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell. The biotechnology firm reported a loss per share of 21 cents, surpassing the ...